|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.040 CAD | -0.74% |
|
+18.13% | +16.76% |
| Capitalization | 99.8M 69.13M 67.54M 63.43M 56.67M 5.96B 113M 777M 288M 2.45B 259M 254M 10.91B | P/E ratio 2025 * |
50.1x | P/E ratio 2026 * | 29.6x |
|---|---|---|---|---|---|
| Enterprise value | 99.8M 69.13M 67.54M 63.43M 56.67M 5.96B 113M 777M 288M 2.45B 259M 254M 10.91B | EV / Sales 2025 * |
0.67x | EV / Sales 2026 * | 0.71x |
| Free-Float |
90.6% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Medexus Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | -0.74% | ||
| 1 week | +18.13% | ||
| Current month | +16.76% | ||
| 1 month | +34.22% | ||
| 3 months | +55.38% | ||
| 6 months | +70.46% | ||
| Current year | +16.76% |
1 week
3.42
4.24
1 month
2.604.24
Current year
3.384.24
1 year
1.474.24
3 years
0.884.24
5 years
0.889.75
10 years
0.889.75
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2018-12-16 | |
Brendon Buschman
DFI | Director of Finance/CFO | - | 2024-06-27 |
Richard Labelle
COO | Chief Operating Officer | - | 2014-02-17 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Mueller
CHM | Chairman | 65 | 2023-04-10 |
Benoit Gravel
BRD | Director/Board Member | - | 2017-09-21 |
| Director/Board Member | - | 2018-10-15 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.74% | +18.13% | +66.26% | +48.53% | 69.13M | ||
| +1.61% | +2.29% | +25.83% | +204.93% | 720B | ||
| +0.37% | -0.82% | -13.26% | +93.04% | 385B | ||
| -0.15% | -1.48% | -11.85% | -17.05% | 342B | ||
| -1.87% | -3.34% | +6.95% | +27.89% | 310B | ||
| -0.60% | +0.11% | -16.20% | +21.53% | 251B | ||
| -1.69% | +4.13% | +6.62% | -28.85% | 234B | ||
| -0.05% | +3.66% | +1.40% | +29.57% | 208B | ||
| -0.60% | +2.33% | -0.25% | +10.15% | 198B | ||
| -0.52% | +0.49% | -5.92% | -52.87% | 151B | ||
| Average | -0.42% | +2.54% | +5.96% | +33.69% | 280.01B | |
| Weighted average by Cap. | -0.03% | +0.73% | +3.01% | +66.08% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 148M 103M 100M 94.17M 84.14M 8.84B 167M 1.15B 428M 3.64B 385M 377M 16.2B | 140M 96.75M 94.54M 88.77M 79.32M 8.34B 157M 1.09B 403M 3.43B 363M 355M 15.27B |
| Net income | 1.83M 1.27M 1.24M 1.16M 1.04M 109M 2.06M 14.23M 5.28M 44.87M 4.75M 4.65M 200M | 3.86M 2.67M 2.61M 2.45M 2.19M 230M 4.35M 30M 11.13M 94.59M 10.02M 9.81M 421M |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
82
Sector
Pharmaceuticals
Calendar
2025-02-04
- Q3 2025 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-10 | 4.040 $ | -0.74% | 305,268 |
| 25-01-09 | 4.070 $ | +13.06% | 130,755 |
| 25-01-08 | 3.600 $ | +4.05% | 76,606 |
| 25-01-07 | 3.460 $ | -0.29% | 66,543 |
| 25-01-06 | 3.470 $ | +1.46% | 88,011 |
Delayed Quote Toronto S.E., January 10, 2025 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.040CAD
Average target price
4.314CAD
Spread / Average Target
+6.79%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MDP Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition